Spots Global Cancer Trial Database for malignant paraganglioma

Every month we try and update this database with for malignant paraganglioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery	NCT03008369	Malignant Adren... Malignant Parag... Metastatic Adre...	Laboratory Biom... Lenvatinib Quality-of-Life...	18 Years -	Mayo Clinic
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	NCT01155258	Extensive Stage... Hereditary Para... Male Breast Can... Malignant Parag... Metastatic Gast... Metastatic Pheo... Pancreatic Poly... Recurrent Breas... Recurrent Cervi... Recurrent Endom... Recurrent Gastr... Recurrent Islet... Recurrent Neuro... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pheoc... Recurrent Prost... Recurrent Renal... Recurrent Small... Recurrent Uteri... Regional Gastro... Regional Pheoch... Stage III Cervi... Stage III Endom... Stage III Neuro... Stage III Ovari... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Uteri... Stage IIIA Brea... Stage IIIA Non-... Stage IIIB Brea... Stage IIIB Non-... Stage IIIC Brea... Stage IV Breast... Stage IV Endome... Stage IV Neuroe... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Uterin... Stage IVA Cervi... Stage IVB Cervi... Thyroid Gland M...	temsirolimus vinorelbine dit...	18 Years -	University of Southern California
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	NCT01155258	Extensive Stage... Hereditary Para... Male Breast Can... Malignant Parag... Metastatic Gast... Metastatic Pheo... Pancreatic Poly... Recurrent Breas... Recurrent Cervi... Recurrent Endom... Recurrent Gastr... Recurrent Islet... Recurrent Neuro... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pheoc... Recurrent Prost... Recurrent Renal... Recurrent Small... Recurrent Uteri... Regional Gastro... Regional Pheoch... Stage III Cervi... Stage III Endom... Stage III Neuro... Stage III Ovari... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Uteri... Stage IIIA Brea... Stage IIIA Non-... Stage IIIB Brea... Stage IIIB Non-... Stage IIIC Brea... Stage IV Breast... Stage IV Endome... Stage IV Neuroe... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Uterin... Stage IVA Cervi... Stage IVB Cervi... Thyroid Gland M...	temsirolimus vinorelbine dit...	18 Years -	University of Southern California
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma	NCT04860700	Malignant Adren... Malignant Parag... Pheochromocytom... Paraganglioma, ... Paraganglioma, ...	anlotinib hydro...	18 Years - 75 Years	Peking Union Medical College Hospital
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer	NCT02592356	Differentiated ... Malignant Adren... Malignant Parag... Thyroid Gland M...	Computed Tomogr... Dual X-ray Abso... Physical Examin... Quality-of-Life... Questionnaire A... Cabozantinib Lenvatinib	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: